AbbVie shares are trading higher after Barclays upgraded the stock from Equal-Weight to Overweight and raised its price target from $160 to $170. Also, Morgan Stanley raised its price target on the stock from $193 to $196.
Portfolio Pulse from Benzinga Newsdesk
AbbVie's stock has been upgraded by Barclays from Equal-Weight to Overweight, with a price target increase from $160 to $170. Morgan Stanley also raised its price target on the stock from $193 to $196.
October 30, 2023 | 2:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie's stock has been upgraded by Barclays and Morgan Stanley, both raising their price targets.
The upgrade from Barclays and the raised price targets from both Barclays and Morgan Stanley indicate a positive outlook for AbbVie. This is likely to increase investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100